HPV Test Guide: When, How, Self-Sampling, and Abroad Options

A human papillomavirus test is now the single most important tool in cervical cancer screening — more sensitive than the Pap smear it largely replaced and recommended as primary screening by the WHO, US Preventive Services Task Force, and most European authorities. This guide explains when to test, how to interpret HR-HPV 16/18 results, where self-sampling kits are approved, and what the test actually costs across the US, UK, Hong Kong, and mainland China.

What Is HPV and How It Causes Cancer

Human papillomavirus is a family of more than 200 related viruses. Around 40 types infect the genital tract, and roughly 14 of those are classified as high-risk (HR-HPV) — meaning they are causally linked to cancer of the cervix, anus, vulva, vagina, penis, and oropharynx.

HPV is the most common sexually transmitted infection worldwide. Most people acquire at least one HPV infection in their lifetime, and the immune system clears around 90 percent of infections within two years. The problem is the persistent 10 percent. When a high-risk HPV infection — most commonly HPV 16 or HPV 18 — sits in cervical tissue for years, it can drive normal cells into precancerous lesions (CIN 1, 2, 3) and eventually into invasive cancer.

The biology is slow. The progression from initial HPV infection to invasive cervical cancer typically takes 10 to 20 years. That long window is exactly why screening works — you can catch and treat precancerous changes long before they become cancer. A well-screened population can reduce cervical cancer incidence by more than 80 percent.

HPV 16 and HPV 18 together cause about 70 percent of cervical cancers globally. That's why modern human papillomavirus test panels report these two genotypes separately, with the remaining 12 high-risk types reported as a pooled result.

HPV Test vs Pap Smear: Which First?

For decades, the Pap smear (cervical cytology) was the standard screening test. A clinician collected cervical cells, sent them to a lab, and a cytopathologist looked under a microscope for abnormal-looking cells. It saved millions of lives, but it has limitations: subjective interpretation, modest sensitivity (around 50-70 percent for a single test), and the need for frequent repeat testing every 1-3 years.

The HPV test detects the virus itself — the upstream cause — using molecular methods (PCR or signal amplification). Sensitivity is roughly 95 percent for detecting cervical precancer in a single test, which is why a negative HPV test gives much stronger reassurance than a negative Pap.

Three screening strategies are in current use:

• HPV primary screening — HPV test alone every 5 years (now recommended in most updated guidelines).
• Co-testing — HPV plus Pap every 5 years (US guidelines for ages 30-65).
• Pap alone — every 3 years for ages 21-29, where HPV testing isn't yet endorsed because young women have high transient infection rates.

If you're 30 or older, the most efficient single test is the human papillomavirus test. If you're between 21 and 29, a Pap smear remains standard in most US guidelines.

Primary HPV Screening (When Pap Isn't Needed)

Primary HPV screening means testing for high-risk HPV first, and only doing further evaluation (Pap, colposcopy) if HPV is positive. This is the model recommended by the WHO and adopted in Australia, the Netherlands, England, and other countries that have switched their national programs.

The logic is straightforward: if you have no high-risk HPV in your cervix, you have essentially no risk of developing cervical cancer in the next 5 years. A single negative HPV test is more reassuring than three negative Paps in a row.

Primary HPV screening is recommended for:

• Women aged 25-65 (some programs start at 30)
• Average risk (no history of CIN 2/3, no immunosuppression, no DES exposure)
• Adequate sample collected by clinician or self-sampling where approved

Screening frequency is every 5 years if HPV-negative. If HPV-positive, reflex Pap or genotyping determines whether you need immediate colposcopy or a 12-month repeat test.

Self-Sampling HPV Kits: Accuracy and Where Approved

Self-sampling — where you collect a vaginal swab yourself, at home or in a clinic restroom — has been a major breakthrough for cervical cancer screening. It removes the discomfort of a speculum exam, increases access for women who avoid clinical screening, and produces accurate results when validated assays are used.

Multiple large studies have shown self-collected vaginal samples perform similarly to clinician-collected cervical samples for detecting high-risk HPV, particularly for HPV 16 and 18. Sensitivity is generally within 5 percentage points of clinician collection.

Where self-sampling is currently approved or in routine national programs:

• Australia — self-collection nationally available since 2022 through GP networks.
• Netherlands and several European countries — self-sampling offered as an alternative for non-responders to standard invitations.
• United States — the FDA approved HPV self-collection in healthcare settings in 2024. At-home self-collection is being rolled out by some commercial labs but is not yet universally available.
• United Kingdom — pilots of self-sampling in the NHS cervical screening program are ongoing in 2025.
• Hong Kong — self-sampling kits available through some private providers.
• Mainland China — not yet part of national screening, but available through private hospitals and online retail kits (quality varies widely; check that the assay is on the WHO list of validated HR-HPV tests).

A reliable self-sampling kit costs $40-$120 depending on country and includes the swab, transport medium, return shipping, and lab processing. Make sure the assay is one of the validated tests (cobas, Aptima, Onclarity, BD Onclarity, or equivalent). Cheap unvalidated kits exist and should be avoided.

Understanding HPV Test Results (HR-HPV 16, 18, Others)

A modern human papillomavirus test result typically reports three things:

• HPV 16 — positive or negative
• HPV 18 — positive or negative
• Other high-risk HPV types pooled — positive or negative (covers types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)

Interpretation depends on which result is positive:

All negative — no high-risk HPV detected. Repeat in 5 years. Very low cancer risk.

HPV 16 positive — highest risk subtype. Almost all guidelines recommend immediate colposcopy regardless of Pap result.

HPV 18 positive — second-highest risk. Most guidelines recommend immediate colposcopy.

Other HR-HPV positive, HPV 16/18 negative — reflex Pap. If Pap is normal, repeat HPV in 12 months. If Pap is abnormal, colposcopy.

Persistent HR-HPV positivity over 12 months — colposcopy, even if specific subtype is "other HR-HPV." Persistence is what causes cancer; transient infection generally doesn't.

The shift toward genotype-specific reporting is what makes the HPV test more clinically actionable than older HPV tests that gave only a pooled "high-risk positive" result. Knowing 16 versus 18 versus other types determines whether you go straight to colposcopy or wait 12 months for a repeat.

If HPV Positive: What Happens Next

A positive HR-HPV result is not a diagnosis of cancer. It means the virus is present and your risk of developing precancerous changes is elevated. What happens next depends on which subtype is positive and your other risk factors.

The typical pathway:

1. Colposcopy — a clinician examines the cervix under magnification, applies acetic acid and iodine solutions to highlight abnormal areas, and takes targeted biopsies of any suspicious patches.
2. Biopsy results — graded as normal, CIN 1 (mild dysplasia), CIN 2 (moderate), or CIN 3 (severe). CIN 1 often resolves on its own. CIN 2/3 usually requires treatment.
3. Treatment for CIN 2/3 — most commonly LEEP (loop electrosurgical excision procedure), which removes the abnormal area. Office-based, 20 minutes, local anesthetic.
4. Follow-up — HPV test at 6 and 12 months after treatment. Most women clear the infection and return to routine screening.

Treatment for high-grade lesions has excellent outcomes. The vast majority of women treated for CIN 2/3 never go on to develop invasive cancer. The whole pathway from HPV positive to all-clear typically takes 6-12 months.

HPV Test Cost: US, UK, Hong Kong, Mainland China

Pricing for a human papillomavirus test varies dramatically by country and care setting:

United States — covered with no copay under ACA preventive care benefits in most insurance plans for women aged 30-65. Self-pay at standalone labs (Quest, LabCorp) runs $100-$250 for the test alone, plus $80-$200 for the office visit if not bundled. At-home self-collection kits from validated providers (e.g., Everlywell, Nurx) cost $80-$120.

United Kingdom — NHS cervical screening (HPV primary, every 3 or 5 years depending on age) is free at point of care. Private screening clinics charge £80-£180 for HPV testing with consultation.

Hong Kong — private clinics charge HK$800-$2,500 ($100-$320 USD) for HPV testing with consultation. Public sector screening is available through the government Cervical Screening Programme for residents.

Mainland China — at Grade 3A hospital international departments, HPV testing typically costs ¥400-¥800 ($55-$110 USD) including the clinician consultation and sample collection. Self-pay imaging-only HPV genotyping at top-tier labs costs ¥300-¥600 ($40-$85 USD).

The price differences reflect labor costs, list-price inflation in the US system, and whether the test is bundled with consultation. The actual lab assay (cobas, Aptima, or equivalent) is the same molecular test worldwide.

Women's Cancer Screening in China for Foreign Patients

For expats and medical tourists, Grade 3A hospitals in mainland China offer comprehensive women's cancer screening at a fraction of US prices, with the same lab assays used globally.

Major hospitals with international departments and women's screening capacity include:

• Peking Union Medical College Hospital (PUMC), Beijing — one of China's top general hospitals, with a strong gynecologic oncology department and full HPV/Pap/colposcopy capability.
• Ruijin Hospital, Shanghai — affiliated with Shanghai Jiao Tong University, offers HPV testing, colposcopy, and LEEP treatment in its international medical center.
• Fudan University Shanghai Cancer Center — China's leading cancer-specialty hospital, with dedicated screening programs for women's cancers.
• HKU-Shenzhen Hospital — Hong Kong University–affiliated, in Shenzhen, with English-language services and strong women's health screening.
• Sun Yat-sen Memorial Hospital, Guangzhou — has a women's health and gynecologic oncology service used by international patients.

A typical women's cancer screening visit in China runs ¥1,500-¥4,000 ($200-$550 USD) and can include HPV genotyping, Pap cytology, breast ultrasound, transvaginal ultrasound, and a gynecologist consultation. Adding tumor markers (CA-125, CA15-3, CEA) typically adds ¥300-¥600.

SinoCareLink is a concierge service — we don't operate hospitals or perform tests ourselves. We help international patients identify the right hospital, book international department appointments, arrange interpretation if needed, and translate reports back to English for your home GP or gynecologist. If your HPV test is positive in China and you need colposcopy, we can coordinate that within the same trip.

For women who travel to China for other reasons (business, family, residence), adding an HPV test or a fuller women's cancer screening to the trip costs almost nothing extra in travel terms — and produces a high-quality molecular result that any Western gynecologist will accept.

Frequently Asked Questions

At what age should I start HPV testing?
Most guidelines recommend starting cervical screening at age 21 (Pap-based in the US) or 25 (HPV-based in many other countries). HPV testing as the primary screen typically starts at age 25 or 30.

How often do I need an HPV test if it's negative?
Every 5 years if you are 25-65, have no history of high-grade lesions, and have a confirmed negative HR-HPV test. This is the WHO and USPSTF recommendation.

Is a self-sampling HPV kit as accurate as a clinician-collected sample?
For high-risk HPV detection, validated self-collection kits perform within about 5 percent of clinician-collected samples. They are good enough that several national programs (Australia, Netherlands) now offer self-sampling as a standard option.

Do I still need a Pap smear if my HPV test is negative?
For most women aged 30-65 with a negative HPV test, no Pap is needed for 5 years. US guidelines do still allow co-testing (HPV + Pap), but primary HPV screening alone is increasingly the standard.

Can men get an HPV test?
There is no FDA-approved HPV test for men in routine screening. HPV-related cancers in men (anal, oropharyngeal, penile) are screened differently. Anal HPV testing is sometimes offered to high-risk groups (men who have sex with men, immunocompromised patients).

Does the HPV vaccine replace screening?
No. Even if you are fully vaccinated (Gardasil 9 covers 9 HPV types), you still need cervical screening. The vaccine prevents most but not all high-risk types, and most adult women were vaccinated after some HPV exposure.

How long does a human papillomavirus test result take?
At commercial labs, results are typically available in 3-7 days. In some Chinese hospital international departments, same-day or next-day results are possible for an additional fee.

Can I get HPV testing during my period?
Heavy menstrual flow can interfere with sample quality. Most labs recommend scheduling outside of your period, though light spotting usually doesn't affect a self-collected sample.

---

Coordinating women's cancer screening in China? Contact us for a coordinated quote →